Insmed (INSM) Short term Debt (2012 - 2024)

Insmed (INSM) posted quarterly Short term Debt of $224.4 million for Q2 2024, little changed quarter-over-quarter from $224.2 million in Q1 2024.

Insmed (INSM) Short term Debt (2012 - 2024) Analysis & Trends

Insmed's Short term Debt history runs 6 years deep, the most recent figure standing at $224.4 million for Q2 2024.

In Q2 2024, Short term Debt changed N/A year-over-year to $224.4 million; the TTM figure through Jun 2024 stood at $224.4 million (changed N/A YoY), while the FY2015 annual figure was $3.1 million, changed N/A from the prior year.
Short term Debt for Q2 2024 stood at $224.4 million, roughly flat from $224.2 million in the prior quarter.
The five-year high for Short term Debt was $224.4 million in Q2 2024, with the low at $224.2 million in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Roivant Sciences	26.16 Bn	26.85 Bn	1.16 Mn

Download Data